---

$0.67

+0.0523 ( +6.96% ) 555.0K

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-08-08	Sale	-3608.00	Paulson Richard A.
2024-07-31	Sale	-2883.00	Poulton Stuart
2024-07-09	Sale	-3616.00	Paulson Richard A.
2024-06-07	Sale	-463518.00	PAKIANATHAN DEEPIKA
2024-06-06	Sale	-3592.00	Paulson Richard A.
2024-06-06	Sale	-652.00	Mason Michael
2024-06-04	Sale	-202418.00	PAKIANATHAN DEEPIKA
2024-05-30	Sale	-69000.00	Schor Chen
2024-05-30	Sale	-69000.00	Mirza Mansoor Raza
2024-05-30	Sale	-69000.00	Oliger Christy J.

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.